These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38901371)

  • 1. Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study.
    Schindler P; Bellmann-Strobl J; Kuhle J; Wildemann B; Jarius S; Paul F; Ruprecht K
    Mult Scler Relat Disord; 2024 Aug; 88():105729. PubMed ID: 38901371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
    J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Kwon YN; Kim B; Kim JS; Park KS; Seo DY; Kim H; Lee EJ; Lim YM; Ju H; Chung YH; Min JH; Nam TS; Kim S; Sohn E; Shin KJ; Seok JM; Kim S; Bae JS; Lee S; Oh SI; Jung YJ; Park J; Kim SH; Kim KH; Kim HJ; Jung JH; Kim SJ; Kim SW; Jang MJ; Sung JJ; Waters P; Shin HY; Kim SM
    JAMA Neurol; 2024 Oct; 81(10):1073-1084. PubMed ID: 39226035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases.
    Ziaei A; Nasr Z; Hart J; Francisco C; Rutatangwa A; Leppert D; Kuhle J; Flanagan E; Waubant E
    Mult Scler Relat Disord; 2023 Jun; 74():104704. PubMed ID: 37031551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
    Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease.
    Kim H; Lee EJ; Kim S; Choi LK; Kim K; Kim HW; Kim KK; Lim YM
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32184342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum NfL and EGFR/NfL ratio mRNAs as biomarkers for phenotype and disease severity of myelin oligodendrocyte glycoprotein IgG-associated disease.
    Wang X; Qu Y; Fan J; Ren H
    Front Immunol; 2024; 15():1388734. PubMed ID: 38807603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.
    Manzano GS; Levy M; Salky R; Mateen FJ; Klawiter EC; Chitnis T; Vasileiou ES; Sotirchos ES; Gibbons E; Huda S; Jacob A; Matiello M
    J Neurol; 2024 Sep; 271(9):6160-6171. PubMed ID: 39066792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of the New Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Diagnostic Criteria in an Israeli Cohort.
    Fineberg A; Lotan I; Bialer O; Tiosano A; Rozenblatt S; Wilf-Yarkoni A; Hellmann MA; Stiebel-Kalish H
    Isr Med Assoc J; 2024 Aug; 26(7):434-440. PubMed ID: 39082453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
    Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD).
    Kwon YN; Kim B; Ahn S; Seo J; Kim SB; Yoon SS; Sung JJ; Choi YS; Kim SM
    J Neuroimmunol; 2020 Nov; 348():577361. PubMed ID: 32919144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain.
    Hyun JW; Kim SY; Kim Y; Park NY; Kim KH; Kim SH; Kim HJ
    Mult Scler; 2022 May; 28(6):993-999. PubMed ID: 34965770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome.
    Wendel EM; Bertolini A; Kousoulos L; Rauchenzauner M; Schanda K; Wegener-Panzer A; Baumann M; Reindl M; Otto M; Rostásy K
    Mult Scler; 2022 Sep; 28(10):1553-1561. PubMed ID: 35282740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks.
    Fonseca E; Olivé-Cirera G; Martinez-Hernandez E; Guasp M; Naranjo L; Ruiz-García R; Caballero E; González-Álvarez V; Delgadillo V; Romeu G; Del-Prado-Sánchez C; Cabrera-Maqueda JM; Benito-León J; Iñiguez C; Garcia-Dominguez JM; Calles C; Cano A; Álvarez-Bravo G; González-Suárez I; Oreja-Guevara C; Ros M; Millan-Pascual J; Meca-Lallana JE; Borrega Canelo L; Martín-Martínez J; Palao M; Gracia J; Villaverde-González R; Llufriu S; Blanco Y; Saiz A; Dalmau J; Sepulveda M; Armangue T;
    Neurology; 2024 Sep; 103(6):e209682. PubMed ID: 39190859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.
    Jarius S; Ringelstein M; Schanda K; Ruprecht K; Korporal-Kuhnke M; Viehöver A; Hümmert MW; Schindler P; Endmayr V; Gastaldi M; Trebst C; Franciotta D; Aktas O; Höftberger R; Haas J; Komorowski L; Paul F; Reindl M; Wildemann B
    J Neurol; 2024 Jul; 271(7):4660-4671. PubMed ID: 38609667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.